Ask AI
Advances in BTK Inhibitor Therapy for B Cell Lymphomas

CE / CME

Advances in BTK Inhibitor Therapy for B-Cell Lymphomas: Expert Discussion and Resources to Elevate Patient Care

Nurse Practitioners/Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: December 11, 2024

Expiration: June 10, 2025

Pretest

Progress
1 2
Course Completed
1.

Which of the following BTK inhibitor is currently approved in combination with obinutuzumab in patients with relapsed or refractory FL after at least 2 previous systemic therapies?

2.

Patient Case 2: 61-Yr-Old Woman With Lymphadenopathy and LUQ pain



  • Patient: 61-yr-old woman with lymphadenopathy and LUQ pain

  • MCL, diffuse variant

  • Ki-67 = 20%

  • TP53 mutation negative

  • Primary therapy: CIT followed by ASCT + rituximab maintenance

    • Relapsed 3 yr later with liver metastases



  • Currently on: zanubrutinib

    • Now experiencing bruising and bleeding (grade 3) 6 mo after starting treatment



Which of the following is the optimal option for this patient experiencing grade 3 bleeding while on a BTK inhibitor?

3.

Rate your confidence in applying current evidence and expert recommendations to maintain patient adherence and persistence to prescribed BTK inhibitors in patients with
B-cell lymphomas?